Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

The Effects of Varenicline on Cognitive Function in Patients With Schizophrenia

This study has been completed.
Stanley Medical Research Institute
Information provided by:
Inje University Identifier:
First received: August 30, 2007
Last updated: August 3, 2009
Last verified: August 2009
The primary objective of this project is to examine the effects of varenicline treatment used concomitantly with antipsychotic medications, on cognitive dysfunction in people with schizophrenia. The secondary objective is to evaluate the effect of this combination therapy on smoking in people with schizophrenia. This study will be a randomized, double blind, parallel group, placebo controlled 8 weeks trial.

Condition Intervention Phase
Drug: Varenicline(Chantix)
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Varenicline, an Alpha 4 Beta 2 Nicotinic Acetylcholine Receptor Partial Agonist, on Cognitive Dysfunction in 120 Patients With Schizophrenia: a Randomized, Double Blind, 8 Weeks Trial

Resource links provided by NLM:

Further study details as provided by Inje University:

Primary Outcome Measures:
  • To examine the effects of varenicline treatment used concomitantly with antipsychotic medications, on cognitive dysfunction in people with schizophrenia. [ Time Frame: 8 weeks ]

Secondary Outcome Measures:
  • To evaluate the effect of this combination therapy on smoking in people with schizophrenia. [ Time Frame: 8 weeks ]

Estimated Enrollment: 120
Study Start Date: September 2007
Study Completion Date: July 2009
Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Varenicline
The effect of varenicline on cognitive function of Varenicline(Chantix) is being compared to that of placebo
Drug: Varenicline(Chantix)
The dose of antipsychotic drug will remain fixed throughout the study and the titration of varenicline will be as follows: varenicline 0.5 mg/d for days 1 to 3, 0.5 mg twice per day for days 4 to 7, then 1 mg twice per day through week 8.
Placebo Comparator: Placebo
The effect of placebo comparator is being compared to that of varenicline
Drug: Placebo
The dose of antipsychotic and concomitant medications remained fixed throughout the study and the titration of varenicline was as follows: Placebo will be supplied twice daily through week 8.

Detailed Description:
Cognitive deficits have been considered as a core symptom domain of schizophrenia. Amelioration of or improvement in cognitive impairments is becoming an important focus of clinical treatment development. Varenicline is a potent and selective alpha 4 beta 2 nicotinic acetylcholine receptor partial agonist that has been developed for smoking cessation. In animal studies, alpha 4 beta 2 receptor agonists significantly improve working memory and attention function. Subjects will be assigned in 1:1 ratio to receive varenicline or placebo respectively. Assessments will be done using several neuropsychologic tests, clinical rating scale including assessment of nicotine withdrawal scales.Varenicline has been found to be efficacious for smoking cessation in the general population and animal studies have demonstrated the cognitive benefits of this agent. However, no published work is available evaluating the cognitive effects in humans. Thus, patients may experience improvements in cognitive function and in people who are smokers, these people may be able to achieve abstinence in smoking. This will in turn improve long-term functional outcomes and health outcomes in people with schizophrenia. This is an exciting opportunity for discovery if indeed cognitive abilities could be improved with this adjunctive treatment.

Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Clinically stable patients with schizophrenia

Exclusion Criteria:

  • Refractory schizophrenia
  • Mental Retardation
  • Serious Medical illness
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00523445

Korea, Republic of
Dongrae Hospital
Busan, Korea, Republic of, 609-370
Busan, Korea, Republic of, 612-827
Busan Paik Hospital
Busan, Korea, Republic of, 614-735
Ahab Hospital
BUsan, Korea, Republic of, 616-824
Dongseo hospital
Masan, Korea, Republic of, 630-856
Sponsors and Collaborators
Inje University
Stanley Medical Research Institute
Principal Investigator: Joo-Cheol Shim, MD.PhD Inje University
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Joo Shim, Inje University Busan Paik Hospital Identifier: NCT00523445     History of Changes
Other Study ID Numbers: Varenicline07
Study First Received: August 30, 2007
Last Updated: August 3, 2009

Keywords provided by Inje University:

Additional relevant MeSH terms:
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Nicotinic Agonists
Cholinergic Agonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs processed this record on May 25, 2017